Boston Scientific Q3 net sales rise 20.3% to $5.065 billion, above company guidance
Boston Scientific reported third-quarter 2025 net sales of $5.065 billion, up 20.3% on a reported basis and 15.3% on an organic basis from a year earlier. GAAP EPS was $0.51 and adjusted EPS was $0.75, both above the company's prior guidance ranges. The company also gave fourth-quarter and full-year 2025 guidance, estimating full-year reported net sales growth of about 20%.
Key points
- Q3 reported net sales of $5.065 billion, up 20.3%, versus guidance of 17% to 19%
- GAAP EPS of $0.51 versus guidance of $0.44 to $0.46; adjusted EPS of $0.75 versus guidance of $0.70 to $0.72
- Q4 2025 guidance: reported net sales growth of 14.5% to 16.5%; GAAP EPS of $0.48 to $0.52; adjusted EPS of $0.77 to $0.79
- Company discontinued worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems in Q2 2025, which had prior year global sales of about $50 million per quarter
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.